Tonix Pharmaceuticals Conference Call Summary Company Overview - **Company**: Tonix Pharmaceuticals (NasdaqCM: TNXP) - **Focus**: Development and commercialization of pharmaceutical products, particularly for fibromyalgia and Lyme disease Key Points on Fibromyalgia Treatment - **Product Launch**: Tonmya, a sublingual cyclobenzaprine, launched on November 17, 2025, is the first new treatment for fibromyalgia in over 15 years [4][5] - **Commercial Transition**: The company has transitioned to a commercial stage over the past two and a half years, acquiring two migraine products to establish its commercial infrastructure [4][5][6] - **Sales Force**: Approximately 90 representatives are actively promoting Tonmya, utilizing omnichannel strategies to connect with healthcare providers [5][6] - **Physician Feedback**: Early anecdotal feedback from physicians indicates positive patient results, with no significant negative surprises reported [9][10] - **Prescriber Demographics**: Prescribers include 30% rheumatologists, 30% primary care physicians, and others from pain management and neurology specialties [10][11] - **Market Positioning**: Tonmya is being positioned as a first-line monotherapy for fibromyalgia, with a focus on patients who may cycle through various treatments due to limited benefits of existing drugs [13][14] Access and Reimbursement - **Payer Coverage**: The company is actively engaging with payers to secure coverage, emphasizing the importance of maintaining reasonable rebates to ensure profitability [20][21] - **Market Dynamics**: The three major payers control over 90% of the market, and the company is hopeful that the value proposition of a non-opioid analgesic will be recognized [22] Key Metrics for Launch Success - **Metrics Monitored**: Total prescriptions, new prescriptions, and the number of unique prescribers are key metrics being tracked to assess the launch's success [23][24] - **Growth Pattern**: The company describes its growth as linear rather than exponential at this stage, with ongoing efforts to increase prescription rates [24][25] Lyme Disease Program - **Product Overview**: The Lyme disease program involves a long-acting monoclonal antibody designed to prevent Lyme disease, with an expected duration of protection from spring to fall [27][28] - **Target**: The antibody targets the OspA protein on Borrelia, the bacteria causing Lyme disease, and is distinct from vaccines as it provides passive immunity [30][31] - **Market Demand**: An estimated 70 million Americans live in Lyme endemic areas, with 500,000 cases reported annually, indicating a significant potential demand for preventative therapy [33] Investor Insights - **Underestimated Aspects**: Investors may not fully appreciate the significance of the launch of Tonmya and the potential of the Lyme disease program, as well as the company's financial position with $208 million in cash and a one-year runway for launch efforts [34][35] Conclusion - **Future Outlook**: The company is optimistic about its growth trajectory and the potential impact of its products on underserved patient populations, particularly in fibromyalgia and Lyme disease [34][35]

Core Viewpoint - Tonix Pharmaceuticals has launched TONMYA, the first FDA-approved treatment for fibromyalgia in over 15 years, demonstrating rapid pain relief and a favorable benefit-risk profile in clinical studies [1][2]. Group 1: Product Overview - TONMYA (cyclobenzaprine HCl sublingual tablets) was approved by the FDA on August 15, 2025, for the treatment of fibromyalgia in adults [9]. - The formulation allows for rapid transmucosal absorption and reduces the production of a long half-life active metabolite, norcyclobenzaprine, due to bypassing first-pass hepatic metabolism [9]. - TONMYA is also being investigated for other conditions, including acute stress reaction, acute stress disorder, and major depressive disorder [9]. Group 2: Clinical Study Results - In the RESILIENT trial, TONMYA showed significant pain reduction as early as Day 2, with a statistically significant change in weekly average daily numeric rating scale (NRS) pain scores (p<0.001) [3]. - The primary endpoint was met with a least-squares mean treatment difference of -0.65, and all key secondary endpoints were statistically significant in favor of TONMYA [3]. - A pooled analysis of the RELIEF and RESILIENT studies indicated that the number needed to treat (NNT) for a clinically meaningful ≥30% pain reduction was 7, while the number needed to harm (NNH) for discontinuation due to adverse events was 26, resulting in a likelihood to be helped or harmed (LHH) of 3.7 [5]. Group 3: Safety and Tolerability - TONMYA was generally well tolerated, with a discontinuation rate due to adverse events of 6.1% compared to 3.5% for placebo [4]. - The most common treatment-emergent adverse events included oral cavity reactions, such as oral hypoesthesia (23.8%) and abnormal product taste (11.7%), which were typically mild and transient [4][6]. - Safety data were consistent with the known profile of TONMYA, with no new or unexpected safety signals reported [6]. Group 4: Market Context - Approximately 10 million adults in the U.S. suffer from fibromyalgia, with a significant unmet medical need for effective treatments [2][8]. - Physicians and patients have expressed dissatisfaction with currently marketed products, highlighting the potential market opportunity for TONMYA [8].

Core Insights - Tonix Pharmaceuticals has launched TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgia treatment, marking the first new prescription medicine for this condition in over 15 years [2][7] - The drug demonstrated statistically significant pain reduction in Phase 3 trials and was well tolerated by patients [1][2] Company Overview - Tonix Pharmaceuticals is a fully integrated biotechnology company focused on central nervous system (CNS) and immunology treatments, addressing high unmet medical needs [8] - The company’s flagship product, TONMYA, is supported by a commercial infrastructure that includes other marketed products for acute migraine [8] Product Details - TONMYA is designed to provide rapid absorption and reduce the formation of the active metabolite norcyclobenzaprine, which can interfere with treatment durability [2][6] - The FDA approved TONMYA in August 2025 based on the results of the Phase 3 RESILIENT trial, which involved 457 patients [2][7] Clinical Trial Results - The Phase 3 RESILIENT trial showed a statistically significant reduction in mean daily pain at 14 weeks, with an increase in the number of patients achieving a 30% reduction in pain compared to placebo [2] - Common adverse events were mild and primarily related to oral cavity reactions, leading to low withdrawal rates from the study [2] Market Context - Fibromyalgia affects an estimated 6-12 million adults in the U.S., with a significant majority being women, and is characterized by chronic pain, fatigue, and sleep disturbances [5] - Current FDA-approved treatments for fibromyalgia are limited by side effects and high discontinuation rates, positioning TONMYA as a promising alternative [2][5]

Core Insights - Tonix Pharmaceuticals has launched TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgia treatment, marking the first new prescription medicine for this condition in over 15 years [2][7] - The drug demonstrated statistically significant pain reduction in Phase 3 trials and was well tolerated by patients [1][2] Company Overview - Tonix Pharmaceuticals is a fully integrated biotechnology company focused on central nervous system (CNS) and immunology treatments, with TONMYA as its flagship product [8] - The company is also developing other treatments, including those for major depressive disorder and acute stress disorder, alongside its immunology pipeline [8] Product Details - TONMYA is designed to provide rapid absorption and reduce the formation of the active metabolite norcyclobenzaprine, which can interfere with treatment efficacy [2][6] - The FDA approved TONMYA in August 2025 based on the results of the Phase 3 RESILIENT trial, which involved 457 patients [2][7] Clinical Trial Results - The Phase 3 RESILIENT trial showed a statistically significant reduction in mean daily pain at 14 weeks, with a notable increase in patients achieving a 30% reduction in pain compared to placebo [2] - Common adverse events were mild and primarily related to oral cavity reactions, leading to minimal study withdrawals [2] Market Context - Fibromyalgia affects an estimated 6-12 million adults in the U.S., predominantly women, and is characterized by chronic pain, fatigue, and sleep disturbances [5] - Current FDA-approved treatments for fibromyalgia have limitations related to side effects and adherence, positioning TONMYA as a promising alternative [2][5]

Core Insights - TONMYA (cyclobenzaprine HCl sublingual tablets) is the first new FDA-approved treatment for fibromyalgia in adults in over 15 years, launched commercially in the U.S. in November 2025 [1] - The formulation is designed for rapid transmucosal absorption, bypassing first-pass liver metabolism, which enhances the durability of analgesic response compared to traditional oral cyclobenzaprine [1][2] - Clinical studies indicate that TONMYA provides a durable analgesic benefit and is generally well tolerated among fibromyalgia patients [2][5] Company Overview - Tonix Pharmaceuticals Holding Corp. is a fully integrated biotechnology company focused on central nervous system (CNS) and immunology treatments, with TONMYA as its flagship product [9] - The company is also developing other treatments, including those for major depressive disorder and acute stress disorder, leveraging its proprietary formulations [9] Product Details - TONMYA utilizes a patented sublingual formulation that enhances drug exposure during sleep while minimizing side effects associated with the active metabolite norcyclobenzaprine [8] - The product is indicated for the treatment of fibromyalgia in adults and is expected to have U.S. market exclusivity until 2034/2035 due to multiple patents [8] Clinical Study Findings - Study 1 demonstrated that the potassium phosphate dibasic formulation of TONMYA achieved a 154% relative bioavailability compared to oral immediate-release cyclobenzaprine, with a significantly shorter absorption lag [3] - Study 2 confirmed the absence of food effects on pharmacokinetic parameters and characterized the active metabolite's elimination half-life as approximately 60 hours [4] Market Context - Fibromyalgia affects an estimated 6-12 million adults in the U.S., predominantly women, and is characterized by chronic pain and other debilitating symptoms [7] - There is a noted dissatisfaction with currently marketed products for fibromyalgia, highlighting the potential market opportunity for TONMYA [7]

Core Insights - Axsome Therapeutics (AXSM) has initiated a phase III study named FORWARD to evaluate AXS-14 (esreboxetine) for managing fibromyalgia, marking a significant step in its drug development process [1][8] - AXS-14 is an investigational oral drug aimed at increasing norepinephrine levels in the brain to alleviate chronic pain and related symptoms associated with fibromyalgia [1] Study Details - The FORWARD study is a phase III double-blind, placebo-controlled withdrawal trial involving patients with fibromyalgia, where participants who respond to treatment during a 12-week open-label period will be randomized to either continue AXS-14 at 8 mg once daily or switch to placebo for up to 12 weeks [2] - The primary endpoint of the study is to measure the time from randomization to the loss of therapeutic response [2][8] Market Performance - Over the past year, AXSM's shares have increased by 89.4%, significantly outperforming the industry average rise of 18.7% [3] Regulatory Background - Axsome submitted a new drug application (NDA) for AXS-14 for fibromyalgia in May 2025, which was delayed from an earlier timeline of the first quarter of 2024 [5] - In June 2025, the FDA issued a Refusal to File (RTF) letter regarding the NDA, citing inadequacies in one of the placebo-controlled studies, prompting Axsome to initiate the FORWARD study to address these concerns [6][8] Disease Context - Fibromyalgia is a chronic neurological pain disorder affecting approximately 17 million people in the United States, characterized by widespread pain, fatigue, sleep disturbances, and other symptoms [7]

Core Insights - Axsome Therapeutics has initiated the FORWARD Phase 3 trial for AXS-14 (esreboxetine) aimed at managing fibromyalgia, marking a significant step in addressing this chronic condition [1][2] Group 1: Trial Details - The FORWARD trial is a Phase 3, double-blind, placebo-controlled, multicenter study involving a randomized withdrawal design [2] - Patients will undergo a 12-week open-label treatment period followed by a randomized phase where they will either continue AXS-14 (8 mg) or switch to a placebo [2] - The primary endpoint is the time from randomization to loss of therapeutic response [2] Group 2: Fibromyalgia Overview - Fibromyalgia affects approximately 17 million people in the U.S., characterized by widespread pain, fatigue, and cognitive impairment [3] - The condition has a significant impact on quality of life and is associated with a considerable economic burden [3] - Current treatment options are limited, with over 50% of patients discontinuing treatment within the first year due to inadequate symptom control or side effects [3] Group 3: AXS-14 Profile - AXS-14 (esreboxetine) is a selective norepinephrine reuptake inhibitor being developed specifically for fibromyalgia management [4] - It is the SS-enantiomer of racemic reboxetine and is currently an investigational drug not yet approved by the FDA [4] Group 4: Company Overview - Axsome Therapeutics focuses on innovative treatments for central nervous system disorders, with a portfolio that includes FDA-approved therapies for various conditions [5] - The company aims to address critical gaps in care and improve patient outcomes through differentiated products [5] - Axsome's mission is to tackle significant neurological and psychiatric challenges affecting over 150 million people in the U.S. [5]

Core Insights - TONMYA is the first FDA-approved treatment for fibromyalgia in over 15 years, providing a novel non-opioid option for patients [1][4] - The drug is now available by prescription nationwide, targeting the estimated 10 million adults in the U.S. suffering from fibromyalgia [2][7] - The approval is based on positive results from two Phase 3 clinical trials, demonstrating significant pain reduction compared to placebo [5][9] Company Overview - Tonix Pharmaceuticals Holding Corp. is a fully integrated biotechnology company focused on central nervous system disorders, immunology, and rare diseases [11] - The company operates a state-of-the-art infectious disease research facility and markets treatments for fibromyalgia and acute migraine [11] Product Details - TONMYA (cyclobenzaprine HCl sublingual tablets) is a patented formulation that allows for rapid absorption and is taken once daily at bedtime [8] - The drug targets neurotransmitters involved in fibromyalgia, marking a significant advancement in treatment options for patients [3][4] Clinical Trial Information - The Phase 3 trials, RELIEF and RESILIENT, involved nearly 1,000 patients and showed that TONMYA significantly reduced daily pain scores at 14 weeks [5][9] - A greater percentage of participants experienced a clinically meaningful improvement in pain after three months compared to those on placebo [5] Market Potential - The approval of TONMYA is expected to address the long-standing need for effective treatments in a patient population that has historically faced limited options [2][3] - The patents associated with TONMYA are expected to provide market exclusivity until 2034, with potential extensions until 2044 [8]

Core Insights - Tonmya™ is set to launch in November 2025, marking the first new FDA-approved treatment for fibromyalgia in over 15 years [1][5] - Tonix Pharmaceuticals reported cash and cash equivalents of $190.1 million as of September 30, 2025, which is expected to fund operations into the first quarter of 2027 [1][8] - The company is focused on successfully launching Tonmya and advancing its pipeline, including TNX-4800 for Lyme disease prevention and TNX-1500 for kidney transplant rejection [2][14] Commercial Updates - Tonmya (cyclobenzaprine HCl sublingual tablets) is a non-opioid analgesic for fibromyalgia treatment [3] - Tosymra (sumatriptan nasal spray) has received preferred exclusive placement on a payer formulary effective January 1, 2026, covering approximately 16 million lives [3] Pipeline Updates - TNX-102 SL is in development for major depressive disorder (MDD) [4] - TNX-1500 is under investigation for kidney transplant rejection prevention and may also treat autoimmune disorders [4] - TNX-4800 is a long-acting monoclonal antibody in development for Lyme disease prevention, with plans for a Phase 2/3 study in 2027 [14] Financial Performance - For Q3 2025, net product revenue was approximately $3.3 million, an increase from $2.8 million in Q3 2024 [9] - Research and development expenses for Q3 2025 were $9.3 million, slightly up from $9.1 million in the same period in 2024 [10] - Selling, general, and administrative expenses surged to $25.7 million in Q3 2025, compared to $7.7 million in Q3 2024, primarily due to Tonmya-related marketing [11] - The net loss for Q3 2025 was $32.0 million, or $3.59 per share, compared to a net loss of $14.2 million, or $22.68 per share, in Q3 2024 [12] Balance Sheet Highlights - As of September 30, 2025, total assets were $252.4 million, with total liabilities at $21.3 million [21] - The company’s stockholders' equity increased to $231.1 million from $139.6 million as of December 31, 2024 [21]

Core Insights - Tonmya demonstrated significant reduction in fibromyalgia pain compared to placebo in the Phase 3 RESILIENT study, indicating its potential as a well-tolerated, non-opioid analgesic for adults with fibromyalgia [1][2] - The treatment was well tolerated with a discontinuation rate of 19% versus 20.8% for placebo, and minimal effects on weight or blood pressure [1][2] Company Overview - Tonix Pharmaceuticals is a fully integrated biotechnology company with marketed products and a pipeline focused on central nervous system disorders, immunology, immuno-oncology, rare diseases, and infectious diseases [4] - The company received FDA approval for Tonmya on August 15, 2025, marking the first new prescription medicine approval for fibromyalgia in over 15 years [3][4] - Tonix also markets treatments for acute migraine and is developing TNX-102 SL for acute stress reaction and major depressive disorder [4] Clinical Study Details - The RESILIENT study was a 14-week randomized, double-blind, placebo-controlled trial involving 456 participants across 34 U.S. sites, meeting the 2016 American College of Rheumatology criteria for fibromyalgia [2] - Statistically significant reductions in weekly average pain scores were observed at Week 14 (p<0.0001) compared to placebo, along with improvements in sleep quality, fatigue, and other fibromyalgia symptoms [2] Treatment Profile - Tonmya's favorable tolerability profile includes minimal impact on weight and blood pressure, no adverse sexual side effects, and a low rate of adverse event-related discontinuations [2][3] - The most common adverse events were mild oral cavity reactions, which rarely led to study withdrawal [2]